Amplify Weight Loss Drug & Treatment ETF Rating $21.99 +0.08 (+0.37%) As of 08/8/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartHoldingsOwnershipRatingsShort InterestBuy This Stock Amplify Weight Loss Drug & Treatment ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.THNR Aggregate RatingModerate Buy 2.51Holdings in THNR have an aggregate rating of Moderate Buy based on 210 analyst ratings issued in the past year covering 12 companies (69.8% of the portfolio).THNR Aggregate Price Target$21.99High Prediction$21.99Average Prediction$21.99Low Prediction$21.99Holdings in THNR have an aggregate price target of $21.99 and a range of $21.99 to $21.99 covering 12 companies (69.8% of the portfolio).THNR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy6 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Amplify Weight Loss Drug & Treatment ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 12 THNR Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings12.15%LLYEli Lilly and Company$625.15-2.5%4.9993 of 5 stars2.67$984.41 57.5%21Trending NewsEarnings ReportAnalyst DowngradeInsider TradeGap UpHigh Trading Volume10.43%NVONovo Nordisk A/S$51.06+4.7%4.1894 of 5 stars2.00$93.67 83.4%13Trending NewsEarnings ReportDividend CutAnalyst DowngradeOptions VolumeGap Up7.27%REGNRegeneron Pharmaceuticals$563.00+0.6%4.915 of 5 stars2.75$832.73 47.9%24News CoveragePositive NewsEarnings ReportDividend AnnouncementAnalyst Revision6.93%AMGNAmgen$288.23+1.2%4.5751 of 5 stars2.33$303.76 5.4%21Trending NewsEarnings ReportDividend AnnouncementAnalyst ForecastAnalyst Revision5.16%MRKMerck & Co., Inc.$80.73+0.4%4.997 of 5 stars2.35$107.44 33.1%20Positive News5.15%ABBVAbbVie$198.10-0.4%4.6899 of 5 stars2.93$214.43 8.2%27Trending NewsAnalyst UpgradeInsider Trade5.13%PFEPfizer$24.57+1.4%4.9851 of 5 stars2.39$28.12 14.4%18Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision5.03%GILDGilead Sciences$119.41+8.3%4.6533 of 5 stars2.80$114.82 -3.8%25Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeGap UpHigh Trading Volume4.78%AZNAstraZeneca$73.56-1.4%3.4645 of 5 stars2.83$89.00 21.0%6Positive NewsAnalyst Revision3.66%HIMSHims & Hers Health$51.87+1.6%2.683 of 5 stars1.92$39.83 -23.2%12Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst Revision2.27%VKTXViking Therapeutics$37.89+6.6%4.0134 of 5 stars3.00$86.92 129.4%14Positive News1.86%CRNXCrinetics Pharmaceuticals$26.85-3.7%3.3631 of 5 stars2.78$69.00 157.0%9News CoverageEarnings ReportHigh Trading Volume This page (NYSEARCA:THNR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amplify Weight Loss Drug & Treatment ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Amplify Weight Loss Drug & Treatment ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
